Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan.

Takeshi Arashiro,Yuzo Arima,Kumi Chubachi,Tadaki Suzuki,Yusuke Nishida,Akihiro Ueda,Kei Yamamoto,Akira Nakamura,Yasuyuki Kato,Katsushi Tanaka,Koya Ariyoshi,Torahiko Jinta,Kankuro Ueshima,Ashley Stucky,Motoi Suzuki,Jin Kuramochi,Tetsuji Fuwa,Hirokazu Muraoka,Atsushi Yanai,Hiroko Arioka,Yuki Nidaira,Takahiro Asami,Genei Ihara,Yuki Uehara,Kunihiro Oba,Naoki Yanagisawa,Daisuke Taniyama,Hideaki Kato,Hideaki Oka,Akira Sato ,Christopher Smith ,Martin L Hibberd

doi:10.1093/ofid/ofad240

Abstract

In this multicenter, prospective, test-negative, case-control study in Japan, the effectiveness of both BA.1-containing and BA.4/BA.5-containing bivalent coronavirus disease 2019 mRNA vaccines against symptomatic infection during the BA.5-dominant period was high compared with no vaccination (65% and 76%) and moderate compared with monovalent vaccines administered over half a year earlier (46% combined).

Full Text